Drug Profile
BLI 1100
Alternative Names: BLI1100Latest Information Update: 04 Oct 2018
Price :
$50
*
At a glance
- Originator Braintree Laboratories
- Class Antiacnes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 04 Oct 2018 No development reported - Phase-II for Acne vulgaris (In adolescents, In adults) in USA (Topical, Gel)
- 01 Jun 2016 Braintree Laboratories completes a phase II trial in Acne vulgaris (In adolescents, In adults) in USA (Topical, Gel) (NCT02604680)
- 01 Oct 2015 Phase-II clinical trials in Acne vulgaris (In adolescents, In adults) in USA (Topical, Gel) (NCT02604680)